Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24821194 | 0.88 | KDM4C (0.45) | MAPTPPARGLMNAMEN1KMT2A | |
| SCHEMBL19985008 | 0.83 | NQO2 (0.43) | NQO2MTNR1AMTNR1BNPSR1CYP1A2 | |
| SCHEMBL11659645 | 0.83 | PPARG (0.45) | NQO2MTNR1AMTNR1BPPARG | |
| SCHEMBL3703857 | 0.80 | SMN1; SMN2 (0.42) | CYP1A2TSHRHPGD | |
| SCHEMBL31686158 | 0.80 | SMN1; SMN2 (0.42) | CYP1A2TSHRHPGD | |
| SCHEMBL31618140 | 0.80 | MPO (0.42) | MAPTPPARGLMNAMEN1KMT2A | |
| SCHEMBL7571658 | 0.79 | DPP9 (0.40) | NQO2MTNR1AMTNR1BPPARG | |
| SCHEMBL9626670 | 0.76 | THRB (0.41) | NQO2MTNR1AMTNR1BLMNAMEN1 | |
| SCHEMBL2590701 | 0.76 | NQO2 (0.48) | NQO2MTNR1AMTNR1BMAPTLMNA | |
| SCHEMBL21538691 | 0.75 | NPC1 (0.41) | MAPTLMNAKMT2ACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571497-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | Sanford-Burnham Medical Research Institute (US) | 2013-03-27 | — | — | EP | claimed |
| CN-103002887-A | Methods and compositions relating to retinoid receptor selective pathways | SANFORD BURNHAM MED RES INST | 2013-03-27 | — | — | CN | claimed |
| WO-2011140525-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-11-10 | — | — | WO | claimed |
| CN-107050007-B | Methods and compositions relating to retinoid receptor selective pathways | 桑福德 - 伯纳姆医学研究所 | 2020-06-30 | — | — | CN | disclosed |
| US-10087156-B2 | Methods and compositions related to retinoid receptor-selective pathway | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-10-02 | — | — | US | disclosed |
| EP-2571497-B1 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | SANFORD BURNHAM MED RES INST (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20170313668-A1 | METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY | Sanford Burnham Prebys Medical Discovery Institute | 2017-11-02 | — | — | US | disclosed |
| US-20170313668-A1 | METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY | Sanford Burnham Prebys Medical Discovery Institute | 2017-11-02 | — | — | US | disclosed |
| US-20170313668-A1 | METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY | Sanford Burnham Prebys Medical Discovery Institute | 2017-11-02 | — | — | US | disclosed |
| US-9611235-B2 | Methods and compositions related to a retinoid receptor-selective pathway | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611235-B2 | Methods and compositions related to a retinoid receptor-selective pathway | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-04-04 | — | — | US | disclosed |
| WO-2011140525-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140525-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20090118290-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY | 2009-05-07 | — | — | US | disclosed |
| US-7491744-B2 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491744-B2 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101031289-A | Indoleacetic and indeneacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | UNIV VANDERBILT (US) | 2007-09-05 | — | — | CN | disclosed |
| EP-1744747-A2 | INDOLEACETIC ACID AND INDENACETIC ACID DERIVATIVES AS THERAPEUTIC AGENTS WITH REDUCED GASTROINTESTINAL TOXICITY | Vanderbilt University (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005112921-A2 | INDOLEACETIC ACID AND INDENACETIC ACID DERIVATIVES AS THERAPEUTIC AGENTS WITH REDUCED GASTROINTESTINAL TOXICITY | VANDERBILT UNIVERSITY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050250839-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313668-A1 | METHODS AND COMPOSITIONS RELATED TO RETINOID RECEPTOR-SELECTIVE PATHWAY | RXRG, RXRB, RXRA | NQO2 3355/4885MTNR1A 574/4885MTNR1B 954/4885 |
| US-20050250839-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | AANAT, FABP2, SI | NQO2 2394/4885MTNR1A 7/4885MTNR1B 14/4885 |
| US-10087156-B2 | Methods and compositions related to retinoid receptor-selective pathway | RXRG, RXRB, RXRA | NQO2 3355/4885MTNR1A 574/4885MTNR1B 954/4885 |
| US-20090118290-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | AANAT, FABP2, SI | NQO2 2394/4885MTNR1A 7/4885MTNR1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.